8/11/2006

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/757,625
Filing Date	01/14/2004
First Named Inventor	Michael Bogenstaetter
Group Art Unit	1624
Examiner Name	~~Thomas C. McKenzie~~ K. Habte
Attorney Docket Number	ORT1614USCNT1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
KH		3,714,179		Tweit	01-30-1973	
↓		3,886,160		Tweit	05-27-1975	
↓		5,030,644		Baldwin et al.	07-09-1991	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	KindCode[5]	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T[6]
KH		JP	02306237	A2	Kato et al.	12-1990		

Examiner Signature		Date Considered	11/29/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS,SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

6/11/2006

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/757,625
Filing Date	01/14/2004
First Named Inventor	Michael Bogenstaetter
Group Art Unit	1624
Examiner Name	~~Thomas C. McKenzie~~ K. Hable
Attorney Docket Number	ORT1614USCNT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
KH		GONZALEZ, F. GARCIA et al.: "Synthesis of 3-aryl(alkyl)-4-(D-*arabino*-tetrahydroxybutyl)imidazolin - 2-thiones"; J. Carbohydrate Research. 22(1972), 436-40.	
		JORDAAN, A. et al.: "The Synthesis of 1-Methyl-5-(α-indolyl)imidzaole"; J. of Heterocyclic Chemistry, 5(5), 723-5 (1968).	
		PHILLIPS, J.G. et al.: Chapter 4. Recent Advance in Histamine H_3 Receptor Agents. Annual Reports in Medicinal Chem., 33, 1998, pages 31-40.	
		SABBATINI, RENATO M.E.: Re: The Cyclotron and PET. In Brain & Mind an electronic magazine about Neuroscience [online]. March, 1997. Retrieved from the Internet <http://www.epub.org.br/cm/n01/pet/petcyclo.htm>.	

Examiner Signature		Date Considered	11/29/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Replacement 1/14/2004

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

Application Number	10/757,625
Filing Date	1/14/04
First Named Inventor	M. Bogenstaetter et al.
Group Art Unit	1624
Examiner Name	McKenzie
Attorney Docket Number	ORT-1614

K. McKenzie

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
KM		ARRANG, J.M. et al.; "Auto-inhibition of brain histamine release mediated by a novel class (h3) of histamine receptor" Nature; April 1983; 302:832-837	
		ASH, A.S.F. et al; "Receptors Mediating Some Actions of Histamine"; Br. J. Pharmac. Chemother.; 1968 27:427-439	
		BARNES, J.C. et al; "The selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo"; Soc. Neurosci. Abstr.; 1993 19:1813	
		Bioworld Today, March 2, 1999, page 3	
		BLACK, J.W. et al.; "Definition and Antagonism of Histamine H2-receptors"; Nature; April 1972; 236:385-390	
		DING, Y. S. et al. "Synthesis of High Specific Activity (+)-and(-)6-[18F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction". J. Med. Chem. (1991) 34:767-771	
		GANELLIN, C.R. et al.; "Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists"; Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.); 1998 331:395-404	
		GARBAG, M. et al; "S-[2-(4-Imidazolyl)ethyl]isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist"; J. Pharmacol. Exp. Ther.; 1992; 263(1):304-310	
		GILATECH, INC.; "Gilatech's first drug candidate begins phase I human clinical trials"; Gilatech Inc. Press Release; November 5, 1998	
		ICHINOSE, M. et al; "Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo"; P.J. Eur. J. Pharmacol; 1989; 174:49-55	
		IMAMURA, M. et al.; "Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release 1,2"; J. Pharmacol, Exp. Ther.; 1994; 271(3):1259-1266	
		JONES, R.G. "Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboylates from Glycine and Substituted Glycine Esters. J Am. Chem Soc. (1949) 71:644-647	
		KORTE, A. et al; "Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Na-Methylhistamine"; Biochem. Biophys. Res. Commun.; May 1990; 168(3):979-986	
		KRAUSE, M. et al.; "The Histamine H3 Receptor-A Target for New Drugs"; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 175-198	
		LEURS, R. et al; "The medicinal chemistry and therapeutic potentials of ligands of the histamine h3 receptor" Prog. Drug. Res.; 1995; 45:107-165	
		LIN, Jian-Sheng et al. "Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat"; Brain Res.; 1990; 523:325-330	
		LINNEY, I.D. et al; "Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists"; J. Med. Chem.; 2000; 43:2362-2370	
		LOVENBERG, T.W. et al; "Cloning and Functional Expression of the Human Histamine H3 Receptor"; Mol. Pharmacol; 1999 55:1101-1107	
		LOVENBERG, T.W. et al. "Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. (2000) 293:771-778	
		MACHIDORI, H. et al; "Zucker obese rats:defect in brain histamine control of feeding"; Brain Res.; 1992; 590:180-186	
		MCLEOD, R.L. et al; "Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist"; Soc. Neurosci. Abstr.; 1998; 22:2010	
		MONTI, J.M. et al; "Effects of selective activation or blockade of the histamine h3 receptor on sleep and wakefulness"; Eur. J. Pharmacol.; 1991; 205:283-287	
		MORISSET, S. et al; "High constitutive activity of native H3 receptors regulates histamine neurons in brain"; Nature; Dec., 2000; 408:860-864	
		ODA, Tamaki et al.; "Molecular Cloning and characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes"; J. Biol. Chem.; Nov. 2000; 275(47):36781-36786	
		PANULA, P. et al.; "Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease"Soc. Neurosci. Abstr.; 1995; 21:1977	
		PHELPS, M.E. "Positron Emission Tomography Provides Molecular Imaging of Biological Processes." Proc. Natl. Acad. Sci. (2000) 97:9226-9233	
✓		PHILLIPS, J.G.; ALI, S.M. "In the Histamine H3 Receptor-A Target for New Drugs" Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 197-222	

Examiner Signature		Date Considered	11/29/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.